Sjogren Syndrome With Keratoconjunctivitis

3

Review clinical trials related to Sjogren Syndrome With Keratoconjunctivitis. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Safety and Efficacy of Topical Infliximab in Autoimmune Dry Eye Disease

Sjögren's syndrome is a condition in which the immune system attacks the body's moisture-producing glands. This often causes severe dry eye, leading to discomfort, irritation, blurred vision, and damage to the eye surface. Inflammation plays an important role in this process, and a protein called TNF-alpha is one of the key drivers. This study will test a new eye drop containing infliximab, a medication that blocks TNF-alpha. The goal is to see whether this treatment can safely improve symptoms and signs of severe dry eye in patients with Sjögren's syndrome.

Participants needed: 38
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Instituto de Oftalmología Fundación Conde de ValencianaUpdated: Jun 26, 2026Locations: 1
Eligibility criteria

Adult patients (≥ 18 years). [+8]

Current use of topical corticosteroids or topical immunomodulators (cyclosporine... [+11]

Status: Recruiting

Evaluating a New Therapy for Dry Eye in Patients With Sjögren's Syndrome

This study will evaluate the effect of TRYPTYR in patients with Sjögren's syndrome-related dry eye disease. The goal is to determine whether TRYPTYR can improve symptoms and signs of dry eye in this specific patient population.

Participants needed: 35
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Center For SightUpdated: Dec 22, 2025Locations: 1
Eligibility criteria

Adults over 18 years old with a diagnosis of dry eye disease (DED) secondary to... [+2]

History of ocular surgery within the past 6 months. [+6]

Status: Not yet recruiting

Autologous Serum Obtained by a Closed-Circuit Collection Device

Autologous serum eye drops (ASED) are an established therapy for ocular surface diseases; however, their preparation can be costly and may not be available due to the need for germ-free conditions. This pilot trial assesses the feasibility of collecting ASED in a closed-circuit system for patients with chronic ocular surface diseases.

Participants needed: 16
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: GIANCARLO FATOBENEUpdated: Jun 10, 2025Locations: 1
Eligibility criteria

≥ 18 years [+2]

Active ocular infection; [+9]